vimarsana.com
Home
Live Updates
New Data Presented at AD/PD™ 2023 Show Biogen's BIIB0
New Data Presented at AD/PD™ 2023 Show Biogen's BIIB0
New Data Presented at AD/PD™ 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease
The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau... | March 29, 2023
Related Keywords
Sweden ,
Gothenburg ,
Vastra Gotalands Lan ,
United States ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Priya Singhal ,
Jack Cox ,
Mike Hencke ,
Youtube ,
Exchange Commission ,
Nasdaq ,
Facebook ,
Biogen Inc ,
Linkedin ,
Twitter ,
Alzheimer Association ,
International Conference On Alzheimer ,
Head Of Development At Biogen ,
International Conference ,
Executive Vice President ,
Safe Harbor ,
Tau Protein ,
Accessed March ,
Tau Topic ,
Accessed February ,
Biogen Inc Stock Exchange ,
News ,
Information ,
Press Release ,
The ,
Iib080 ,
Hase ,
Tb ,
Linical ,
Study ,
Us ,
First ,
O ,
Show ,
Reduction ,
F ,
This ,
Magnitude ,
N ,
Au ,
Pet ,
Cross ,
Rain ,
Egionsphase ,
Howed ,
End ,
Sustained ,
F Biib Us09062x1037 ,